KRN633 KRN-633 CAS: 286370-15-8

CAS NO: 286370-15-8
KRN633 KRN-633
Chemical Name: KRN 633
Molecular Formula: C20H21ClN4O4
Formula Weight: 416.86
CAS No.: 286370-15-8
Description Review
Description

KRN633 (also known as KRN-633) is a small molecule inhibitor that has been developed to target the vascular endothelial growth factor receptor 2 (VEGFR-2) signaling pathway. This product has shown potential as a therapeutic agent for various types of cancer, including breast and lung cancer.

Chemical name: (Z)-N-(3-fluoro-4-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)phenyl)-2-(pyridin-2-yl)but-2-enamide

Molecular formula: C33H36FN5O4

Formula weight: 575.67 g/mol

CAS No: 286370-15-8

Top ten keywords from Google:

  1. VEGFR-2 inhibitor
  2. Cancer therapy
  3. Angiogenesis inhibition
  4. Small molecule drug
  5. Clinical trials
  6. Therapeutic potential
  7. Anti-tumor effects
  8. Breast cancer treatment
  9. Lung cancer treatment
  10. Solid tumor therapy

Synonyms:

  • KRN-633
  • KRN633
  • (Z)-N-(3-fluoro-4-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)phenyl)-2-(pyridin-2-yl)but-2-enamide

Health benefits of this product: The primary health benefit of KRN633 is its potential ability to inhibit the VEGFR-2 signaling pathway, which is involved in angiogenesis and tumor growth. By inhibiting VEGFR-2, KRN633 may prevent the formation of new blood vessels in tumors, thereby reducing their size and slowing their progression.

Potential effects: Due to its ability to inhibit VEGFR-2, KRN633 has shown promise as a therapeutic agent for various types of cancers, including breast and lung cancer. In preclinical studies, KRN633 has been shown to significantly reduce tumor growth and increase survival rates in animal models.

Product mechanism: KRN633 works by selectively inhibiting the activity of VEGFR-2, which is responsible for promoting the formation of new blood vessels in tumors. By inhibiting VEGFR-2, KRN633 can prevent the formation of new blood vessels, leading to reduced tumor growth and progression.

Safety: Although KRN633 has shown promising results in preclinical studies, its safety profile in humans is still being studied. In clinical trials, some adverse effects have been reported, including fatigue, nausea, and vomiting, among others. However, these side effects were generally mild and well-tolerated.

Side effects: As with any medication, there is a risk of side effects when taking KRN633. Some potential side effects include headache, fatigue, dizziness, nausea, vomiting, and diarrhea. If you experience any of these symptoms while taking KRN633, you should consult your healthcare provider immediately.

Dosing information: The optimal dosing regimen for KRN633 has not yet been established. However, current clinical trials are investigating doses ranging from 100mg to 500mg per day. Patients should follow their healthcare provider's instructions regarding dosing and administration.

Conclusion: KRN633 is a promising new VEGFR-2 inhibitor that has shown significant potential as an anti-tumor agent in preclinical studies. Although its safety and efficacy in humans are still being evaluated, early results suggest that it may be a valuable addition to the arsenal of cancer therapies. As further research is conducted, KRN633 may prove to be a valuable tool in the fight against cancer

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code